Movatterモバイル変換

[0]ホーム

Jump to content

Mazdutide

Edit links

From Wikipedia, the free encyclopedia

GLP1 poly-agonist drug

Pharmaceutical compound

Mazdutide
Clinical data
Other names	IBI362; LY3305677
Routes of administration	Injection
Legal status
Legal status	Rx in China, Investigational in general
Identifiers
IUPAC name 20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
CAS Number	2259884-03-0
PubChemCID	167312357
DrugBank	DB19099
ChemSpider	129341158
UNII	MB76Z4IBZ5
Chemical and physical data
Formula	C₂₁₀H₃₂₂N₄₆O₆₇
Molar mass	4563.141 g·mol⁻¹
SMILES CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(N)=O
InChI InChI=1S/C210H322N46O67/c1-117(2)93-145(191(300)233-139(70-76-170(276)277)181(290)224-107-164(269)222-109-168(273)256-86-46-57-159(256)204(313)249-157(112-259)203(312)247-155(110-257)183(292)223-106-161(216)266)237-192(301)146(94-118(3)4)239-196(305)152(100-128-104-221-134-52-37-36-51-132(128)134)243-190(299)143(73-79-173(282)283)236-205(314)176(120(7)8)253-199(308)150(96-124-47-30-28-31-48-124)241-189(298)142(72-78-172(280)281)234-185(294)136(56-41-45-83-218-166(271)114-322-91-90-321-88-85-220-167(272)115-323-92-89-320-87-84-219-162(267)75-69-144(208(317)318)228-163(268)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-169(274)275)229-179(288)121(9)227-184(293)135(53-38-42-80-211)230-186(295)137(54-39-43-81-212)231-188(297)141(71-77-171(278)279)235-197(306)153(102-174(284)285)244-193(302)147(95-119(5)6)238-194(303)148(98-126-60-64-130(263)65-61-126)240-187(296)138(55-40-44-82-213)232-201(310)156(111-258)248-195(304)149(99-127-62-66-131(264)67-63-127)242-198(307)154(103-175(286)287)245-202(311)158(113-260)250-207(316)178(123(11)262)254-200(309)151(97-125-49-32-29-33-50-125)246-206(315)177(122(10)261)252-165(270)108-225-182(291)140(68-74-160(215)265)251-209(319)210(12,13)255-180(289)133(214)101-129-105-217-116-226-129/h28-33,36-37,47-52,60-67,104-105,116-123,133,135-159,176-178,221,257-264H,14-27,34-35,38-46,53-59,68-103,106-115,211-214H2,1-13H3,(H2,215,265)(H2,216,266)(H,217,226)(H,218,271)(H,219,267)(H,220,272)(H,222,269)(H,223,292)(H,224,290)(H,225,291)(H,227,293)(H,228,268)(H,229,288)(H,230,295)(H,231,297)(H,232,310)(H,233,300)(H,234,294)(H,235,306)(H,236,314)(H,237,301)(H,238,303)(H,239,305)(H,240,296)(H,241,298)(H,242,307)(H,243,299)(H,244,302)(H,245,311)(H,246,315)(H,247,312)(H,248,304)(H,249,313)(H,250,316)(H,251,319)(H,252,270)(H,253,308)(H,254,309)(H,255,289)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,317,318)/t121-,122+,123+,133-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,176-,177-,178-/m0/s1 Key:NCZIWZAVWHEUKM-SQZAUUIPSA-N

Mazdutide (also known as IBI362 or LY3305677) is a dualagonist of theGLP-1 receptor andglucagon receptor. It is an analog ofoxyntomodulin (OXM).^[1]^[2]^[3] The drug is developed byEli Lilly andInnovent Biologics. and is currently in multiple Phase III studies.^[4]^[5] In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults withoverweight orobesity.^[6]

In June 2025, Mazdutide injection is approved for marketing in China.^[7]

References

[edit]

^Jiang, Hongwei; Pang, Shuguang; Zhang, Yawei; Yu, Ting; Liu, Meng; Deng, Huan; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei; Yang, Wenying (24 June 2022)."A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes".Nature Communications.13 (1): 3613.Bibcode:2022NatCo..13.3613J.doi:10.1038/s41467-022-31328-x.ISSN 2041-1723.PMC 9232612.PMID 35750681.
^Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei (December 2022)."Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial".eClinicalMedicine.54 101691.doi:10.1016/j.eclinm.2022.101691.PMC 9561728.PMID 36247927.
^Ji, Linong; Jiang, Hongwei; An, Pei; Deng, Huan; Liu, Meng; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei (September 2021)."IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study".eClinicalMedicine.39 101088.doi:10.1016/j.eclinm.2021.101088.PMC 8374649.PMID 34430840.
^Deswal, Phalguni (2024-09-12)."EASD 2024: Innovent shows off mazdutide's efficacy in diabetes and obesity".Clinical Trials Arena. Retrieved2024-11-10.
^"Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?". 11 May 2023. Retrieved4 November 2023.
^Linong Ji, Hongwei Jiang, Yan Bi, Hua Li, Junhang Tian, Dexue Liu, Yuzhu Zhao, Wei Qiu, Chongbing Huang, Lei Chen, Shao Zhong, Jie Han, Yawei Zhang, Qiufang Lian, Ping Yang, Lingchun Lv, Jieyu Gu, Zihan Liu, Huan Deng, Yanqi Wang, Li Li, Lijuan Pei, Lei Qian (24 May 2025)."Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight".New England Journal of Medicine.392 (22):2215–2225.doi:10.1056/NEJMoa2411528.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^"国家药监局批准玛仕度肽注射液上市".nmpa.gov.cn. 2025-06-27. Retrieved2025-07-05.

Oraldiabetes medication,insulins andinsulin analogues, and other drugs used in diabetes (A10)

Insulins andinsulin analogues

Fast-acting	Insulin aspart Insulin glulisine Insulin lispro
Short-acting	Regular insulin^#
Long-acting	Insulin detemir^# Insulin glargine^# (+lixisenatide) NPH insulin Lente insulin^‡ Ultralente insulin^‡
Ultra-long-acting	Insulin degludec^# (+insulin aspart,+liraglutide) Insulin efsitora^† Insulin icodec^† (+semaglutide)
Inhalable	Exubera^‡ Afrezza
Oral	Insulin tregopil^†

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Non-insulins

Insulin sensitizers

Biguanides	Buformin^‡ Metformin^# Phenformin^‡
TZDs ("-glitazones") andPPAR agonists	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡
Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§
Amylin analogues andDACRAs	Cagrilintide^§ Pramlintide

Secretagogues

K⁺_ATP

Sulfonylureas	1st generation:Acetohexamide Carbutamide Chlorpropamide Glycyclamide Metahexamide Tolazamide Tolbutamide 2nd generation:Glibenclamide (glyburide) Glibornuride Glicaramide Gliclazide^# Glimepiride Glipizide Gliquidone Glisoxepide Glyclopyramide
Meglitinides ("-glinides")	Mitiglinide Nateglinide Repaglinide

GLP-1 receptor agonists

GLP1 poly-agonist peptides	Mazdutide (GLP-1/GCGR) Retatrutide^§ (GLP-1/GIP/GCGR) Tirzepatide (GLP-1/GIP)

DPP-4 inhibitors ("-gliptins")

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§
Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose
SGLT2 inhibitors ("-gliflozins")	Canagliflozin Dapagliflozin Empagliflozin^# Ertugliflozin Ipragliflozin Luseogliflozin Remogliflozin^§ Sergliflozin^§ Sotagliflozin Tofogliflozin^† Velagliflozin
Other	Benfluorex^‡ Bromocriptine Imeglimin

Combinations

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mazdutide&oldid=1330435933"

Categories:

Hidden categories:

[8]ページ先頭